Cargando…

Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients

OBJECTIVE: Differences in efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) have been observed between non-small cell lung cancer (NSCLC) patients with 19 exon deletion (19Del) and L858R mutation. We explored whether the total number or pattern of concomitant mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Hengrui, Li, Caichen, Zhao, Yi, Zhao, Shen, Huang, Jun, Cai, Xiuyu, Cheng, Bo, Xiong, Shan, Li, Jianfu, Wang, Wei, Zhu, Changbin, Li, Weiwei, He, Jianxing, Liang, Wenhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509478/ https://www.ncbi.nlm.nih.gov/pubmed/32982456 http://dx.doi.org/10.2147/CMAR.S255967

Ejemplares similares

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

The impact of postoperative EGFR-TKIs treatment on residual GGO lesions after resection for lung cancer
por: Cheng, Bo, et al.
Publicado: (2021)

The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutations
por: Jiang, Yu, et al.
Publicado: (2023)

Diagnostic Accuracy of Droplet Digital PCR and Amplification Refractory Mutation System PCR for Detecting EGFR Mutation in Cell-Free DNA of Lung Cancer: A Meta-Analysis
por: Li, Caichen, et al.
Publicado: (2020)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Dynamic monitoring serum tumor markers to predict molecular features of EGFR‐mutated lung cancer during targeted therapy
por: Chen, Zhuxing, et al.
Publicado: (2022)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
por: Wu, Xuan, et al.
Publicado: (2013)

Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with EGFR-TKIs
por: Leonetti, Alessandro, et al.
Publicado: (2021)

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
por: Huang, Chu-Ying, et al.
Publicado: (2015)

Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
por: Tudor, Roxana Alina, et al.
Publicado: (2017)

The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
por: Lin, Chutong, et al.
Publicado: (2021)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations
por: Ma, Yihan, et al.
Publicado: (2016)

Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation
por: Peng, Liang, et al.
Publicado: (2015)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
por: Wang, Yujia, et al.
Publicado: (2021)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
por: Liu, Si‐Yang, et al.
Publicado: (2020)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs
por: He, Cheng, et al.
Publicado: (2019)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis
por: Lv, Fangfang, et al.
Publicado: (2021)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
por: Ito, Takashi, et al.
Publicado: (2021)

Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFR(mut) NSCLC in diagnosis, follow-up and treatment
por: Lüke, Florian, et al.
Publicado: (2018)

Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study
por: An, Ning, et al.
Publicado: (2019)

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy
por: Lin, Jing, et al.
Publicado: (2022)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
por: Wu, Hong, et al.
Publicado: (2015)

The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer
por: Bai, Hao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mdo5q8tht2ubv43qak3nakm4to